Cardiovascular disease and toxicities related to HIV infection and its therapies

Karolina M. Zareba, Tracie L Miller, Steven E Lipshultz

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Cardiovascular manifestations of HIV vary according to disease stage, treatment regimen and geographical location. Common cardiac complications of HIV disease in patients off highly active antiretroviral therapy (HAART) include dilated cardiomyopathy, myocarditis, pericardial effusion, endocarditis, pulmonary hypertension and non-antiretroviral drug-related cardiotoxicity. However, with the introduction of HAART that has substantially modified the course of HIV disease by lengthening survival, additional cardiovascular consequences are a result of the metabolic syndrome with a propensity toward hyperlipidaemia and atherosclerotic heart disease. Because most of the world's HIV-infected patients have not been treated with HAART, the principal HIV-associated cardiovascular manifestations of patients off HAART are reviewed and new knowledge about the prevalence, pathogenesis and treatment in the HAART era are emphasised in this review. Exercise, a nonpharmacological approach to treating HAART-associated metabolic syndrome, is also discussed.

Original languageEnglish
Pages (from-to)1017-1025
Number of pages9
JournalExpert Opinion on Drug Safety
Volume4
Issue number6
DOIs
StatePublished - Nov 1 2005

Fingerprint

Highly Active Antiretroviral Therapy
HIV Infections
Cardiovascular Diseases
HIV
Therapeutics
Pericardial Effusion
Myocarditis
Dilated Cardiomyopathy
Endocarditis
Hyperlipidemias
Pulmonary Hypertension
Heart Diseases
Exercise
Survival
Pharmaceutical Preparations

Keywords

  • AIDS
  • Cardiomyopathy
  • Cardiotoxicity
  • Dyslipidaemia
  • Exercise
  • Highly active antiretroviral theraphy (HAART)
  • HIV

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cardiovascular disease and toxicities related to HIV infection and its therapies. / Zareba, Karolina M.; Miller, Tracie L; Lipshultz, Steven E.

In: Expert Opinion on Drug Safety, Vol. 4, No. 6, 01.11.2005, p. 1017-1025.

Research output: Contribution to journalArticle

Zareba, Karolina M. ; Miller, Tracie L ; Lipshultz, Steven E. / Cardiovascular disease and toxicities related to HIV infection and its therapies. In: Expert Opinion on Drug Safety. 2005 ; Vol. 4, No. 6. pp. 1017-1025.
@article{fad88e3dd3174e48bd2a3fdc98eb7ace,
title = "Cardiovascular disease and toxicities related to HIV infection and its therapies",
abstract = "Cardiovascular manifestations of HIV vary according to disease stage, treatment regimen and geographical location. Common cardiac complications of HIV disease in patients off highly active antiretroviral therapy (HAART) include dilated cardiomyopathy, myocarditis, pericardial effusion, endocarditis, pulmonary hypertension and non-antiretroviral drug-related cardiotoxicity. However, with the introduction of HAART that has substantially modified the course of HIV disease by lengthening survival, additional cardiovascular consequences are a result of the metabolic syndrome with a propensity toward hyperlipidaemia and atherosclerotic heart disease. Because most of the world's HIV-infected patients have not been treated with HAART, the principal HIV-associated cardiovascular manifestations of patients off HAART are reviewed and new knowledge about the prevalence, pathogenesis and treatment in the HAART era are emphasised in this review. Exercise, a nonpharmacological approach to treating HAART-associated metabolic syndrome, is also discussed.",
keywords = "AIDS, Cardiomyopathy, Cardiotoxicity, Dyslipidaemia, Exercise, Highly active antiretroviral theraphy (HAART), HIV",
author = "Zareba, {Karolina M.} and Miller, {Tracie L} and Lipshultz, {Steven E}",
year = "2005",
month = "11",
day = "1",
doi = "10.1517/14740338.4.6.1017",
language = "English",
volume = "4",
pages = "1017--1025",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Cardiovascular disease and toxicities related to HIV infection and its therapies

AU - Zareba, Karolina M.

AU - Miller, Tracie L

AU - Lipshultz, Steven E

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Cardiovascular manifestations of HIV vary according to disease stage, treatment regimen and geographical location. Common cardiac complications of HIV disease in patients off highly active antiretroviral therapy (HAART) include dilated cardiomyopathy, myocarditis, pericardial effusion, endocarditis, pulmonary hypertension and non-antiretroviral drug-related cardiotoxicity. However, with the introduction of HAART that has substantially modified the course of HIV disease by lengthening survival, additional cardiovascular consequences are a result of the metabolic syndrome with a propensity toward hyperlipidaemia and atherosclerotic heart disease. Because most of the world's HIV-infected patients have not been treated with HAART, the principal HIV-associated cardiovascular manifestations of patients off HAART are reviewed and new knowledge about the prevalence, pathogenesis and treatment in the HAART era are emphasised in this review. Exercise, a nonpharmacological approach to treating HAART-associated metabolic syndrome, is also discussed.

AB - Cardiovascular manifestations of HIV vary according to disease stage, treatment regimen and geographical location. Common cardiac complications of HIV disease in patients off highly active antiretroviral therapy (HAART) include dilated cardiomyopathy, myocarditis, pericardial effusion, endocarditis, pulmonary hypertension and non-antiretroviral drug-related cardiotoxicity. However, with the introduction of HAART that has substantially modified the course of HIV disease by lengthening survival, additional cardiovascular consequences are a result of the metabolic syndrome with a propensity toward hyperlipidaemia and atherosclerotic heart disease. Because most of the world's HIV-infected patients have not been treated with HAART, the principal HIV-associated cardiovascular manifestations of patients off HAART are reviewed and new knowledge about the prevalence, pathogenesis and treatment in the HAART era are emphasised in this review. Exercise, a nonpharmacological approach to treating HAART-associated metabolic syndrome, is also discussed.

KW - AIDS

KW - Cardiomyopathy

KW - Cardiotoxicity

KW - Dyslipidaemia

KW - Exercise

KW - Highly active antiretroviral theraphy (HAART)

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=27944441787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944441787&partnerID=8YFLogxK

U2 - 10.1517/14740338.4.6.1017

DO - 10.1517/14740338.4.6.1017

M3 - Article

VL - 4

SP - 1017

EP - 1025

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 6

ER -